“Biologics have become an important tool in the treatment of asthma and other allergic diseases such as atopic dermatitis [eczema], chronic rhinosinusitis with nasal polyps and eosinophilic esophagitis, and can prevent substantial ill results from occurring in patients who are eligible for them,” Ca...
atopic eczemaatopic dermatitisBronchial asthmaBiologics, in the narrower sense molecular antibodies, are a modern approach also in the therapy of respiratory and allergological diseases. A targeted selection depending on the phenotype and endotype offers the possibility of an individual treatment. This ...
it is not right for every patient. "I would suggest to you that if you are not practicing OIT don't worry about that," he said. "It is not a perfect therapy and many patients do very well practicing avoidance. They may actually have a better quality of life than many patients on OI...
Taltz is approved to treat adults and children 6 years and older with moderate to severe plaque psoriasis who may benefit from taking injections or pills (systemic therapy) or treatment using ultraviolet or UV light (phototherapy). Taltz is also approved for adult patients with active psoriatic ar...
The signals we have detected will be examined for validity using the same robust analytical pipeline in PSORT, which we show is substantially powered to detect true biomarkers of response to therapy. Likewise, as omics techniques are applied to other dermatological diseases such as atopic eczema (...
Regeneron Pharmaceuticals' (REGN) shares were up 2.7% on the news that the FDA has granted Breakthrough Therapy designation to its eye drug Eylea, for the treatment of diabetic retinopathy in patients suffering from diabetic macular edema.
Earlier this year, the FDA granted Breakthrough Therapy designation for Dupixent as an add-on maintenance treatment in adult patients with uncontrolled COPD associated with a history of exacerbations and an eosinophilic phenotype based on the positive results from BOREAS. “This is...
Absence of need for rescue therapy during treatment period: 42% vs. 12% (nominal p=0.0004) Achievement of complete remission and off OCS by week 16: 38% vs. 27% (not significant) *Components were not separately included in pre-specified statistical analyses and are therefore ...
s priorities.1 Therapy has improved considerably in the last 5 years with the approval of biologics for the treatment of severe disease.3 However, these treatments remain inaccessible to the majority of patients3 and are an expensive treatment option.1 The challenge for practitioners is to apply ...
People 6 years of age and older with moderate to severe plaque psoriasis who may benefit from taking injections or pills (systemic therapy) or treatment using ultraviolet or UV light (phototherapy). Adults with active psoriatic arthritis.